Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Background: The investigator hypothesized that the combined use of pregabalin and paroxetine
would be associated with comparable Somatic Symptoms Scale-8 (SSS-8) and higher tolerability
than amitriptyline or venlafaxine.
Methods: After ethical approval, 75 patients with diagnosed fibromyalgia who were receiving
pregabalin 75 mg/day, were randomly allocated to receive amitriptyline 25 mg/day (n = 24),
venlafaxine 75 mg/day (n = 25), or paroxetine 25 mg/day (n = 26). All patients were assessed
bi-monthly for consequent six months for the changes in the SSS-8, Center for Epidemiological
Studies Depression Scale (CESDS), life satisfaction, mood, sleep quality, fatigue and
medication tolerability and adverse effects.